2. Signaling Pathways
  3. Immunology/Inflammation
  4. COX
  5. COX Isoform
  6. COX Inhibitor

COX Inhibitor

COX Inhibitors (502):

Cat. No. Product Name Effect Purity
  • HY-W740572
    O-Desmethyl-N-deschlorobenzoyl Indomethacin
    		Inhibitor
    O-Desmethyl-N-deschlorobenzoyl indomethacin is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor indomethacin (HY-14397). It is formed from indomethacin in isolated rabbit hepatocytes. O-Desmethyl-N-deschlorobenzoyl indomethacin (600 μM) decreases the viability of HL-60 leukemia cells when cultured with glucose oxidase. It has also been used in the synthesis of prostaglandin D2 (HY-101988) receptor antagonists.
  • HY-B0138R
    Ketorolac (tromethamine salt) (Standard)
    		Inhibitor
    Ketorolac (tromethamine salt) (Standard) is the analytical standard of Ketorolac (tromethamine salt). This product is intended for research and analytical applications. Ketorolac tromethamine salt (RS37619 tromethamine salt) is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2.
  • HY-15762R
    Valdecoxib (Standard)
    		Inhibitor
    Valdecoxib (Standard) is the analytical standard of Valdecoxib. This product is intended for research and analytical applications. Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
  • HY-N0774R
    Isofraxidin (Standard)
    		Inhibitor
    Isofraxidin (Standard) is the analytical standard of Isofraxidin. This product is intended for research and analytical applications. Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits MMP-7 expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of ERK1/2 in hepatoma cells. Isofraxidin attenuates the expression of iNOS and COX-2, Isofraxidinalso inhibits TLR4/myeloid differentiation protein-2 (MD-2) complex formation.
  • HY-168766
    O-Acetylsalicylhydroxamic acid
    		Inhibitor
    O-Acetylsalicylhydroxamic acid is an acetylation inhibitor of prostaglandin H2 synthase that can suppress PGE2 synthesis in the body and block the cyclooxygenase activity of PGHS in vitro. O-Acetylsalicylhydroxamic acid requires the presence of the active site residue Ser-529 to act on human PGHS-1; the S529A mutant is resistant to the inactivation effects of this inhibitor.
  • HY-N6968R
    α-Humulene (Standard)
    		Inhibitor
    α-Humulene (Standard) is the analytical standard of α-Humulene. This product is intended for research and analytical applications. α-Humulene is a main constituent of Tanacetum vulgare L. (Asteraceae) essential oil with anti-inflammation (IC50=15±2 μg/mL). α-Humulene inhibits COX-2 and iNOS expression.
  • HY-120232
    ABT-963
    		Inhibitor
    ABT-963 is a selective cyclooxygenase-2 (COX-2) inhibitor for the study of pain and inflammation.
  • HY-17474R
    Parecoxib (Standard)
    		Inhibitor
    Parecoxib (Standard) is the analytical standard of Parecoxib. This product is intended for research and analytical applications. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
  • HY-B0167AR
    Sodium Salicylate (Standard)
    		Inhibitor
    Sodium Salicylate (Standard) is the analytical standard of Sodium Salicylate. This product is intended for research and analytical applications. Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a S6K inhibitor.Sodium Salicylate is a NF-κB inhibitor that decreases inflammatory gene expression and improves repair in aged muscle.
  • HY-N15272
    Artocarpesin
    		Inhibitor
    Artocarpesin is a flavonoid compound. Artocarpesin has inhibitory effects on methicillin-resistant Staphylococcus aureus (MRSA). Artocarpesin inhibits the production of NO, PGE2 and ROS by inhibiting COX-2 and iNOS expression, and plays an anti-inflammatory role. In addition, Artocarpesin inhibits platelet aggregation by inhibiting cyclic nucleotides and MAPKs, which can be used in the study of cardiovascular diseases.
  • HY-B2137S
    S-(+)-Ketoprofen-d3
    		Inhibitor
    S-(+)-Ketoprofen-d3 ((S)-Ketoprofen-d3) is deuterium labeled S-(+)-Ketoprofen. S-(+)-Ketoprofen is a potent inhibitor of both COX-1 and COX-2 with IC50s of 1.9 and 27 nM, respectively.
  • HY-10582R
    Flurbiprofen (Standard)
    		Inhibitor
    Flurbiprofen (Standard) is the analytical standard of Flurbiprofen. This product is intended for research and analytical applications. Flurbiprofen (dl-Flurbiprofen) is a potent, orally active nonsteroidal anti-inflammatory agent (NSAIA/NSAID), with antipyretic and analgesic activities. Flurbiprofen is commonly used for the research of inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Flurbiprofen is a non-selective cyclooxygenase (COX) inhibitor that can be used for the research of colorectal cancer.
  • HY-17009R
    Iguratimod (Standard)
    		Inhibitor
    Iguratimod (Standard) is the analytical standard of Iguratimod. This product is intended for research and analytical applications. Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.
  • HY-157583
    COX-2-IN-39
    		Inhibitor
    COX-2-IN-39 (compound 44) is a potent inhibitor of COX-2, with the IC50 value of 0.4 nM.
  • HY-78131AR
    (S)-(+)-Ibuprofen (Standard)
    		Inhibitor
    (S)-(+)-Ibuprofen (Standard) is the analytical standard of (S)-(+)-Ibuprofen. This product is intended for research and analytical applications. (S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.
  • HY-W654009
    Loxoprofen-d3
    		Inhibitor
    Loxoprofen-d3 is deuterium labeled Loxoprofen. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity.
  • HY-B0440R
    Tenoxicam (Standard)
    		Inhibitor
    Tenoxicam (Standard) is the analytical standard of Tenoxicam. This product is intended for research and analytical applications. Tenoxicam (Ro-12-0068), an antiinflammatory agent with analgesic and antipyretic properties.
  • HY-B0578R
    Loxoprofen (Standard)
    		Inhibitor
    Loxoprofen (Standard) is the analytical standard of Loxoprofen. This product is intended for research and analytical applications. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity.
  • HY-107336
    Cyclovalone
    		Inhibitor
    Cyclovalone (Beveno) is a synthetic curcumin derivate, which inihibits cyclooxygenase and exhibits anti-inflammatory, antitumor and antioxidant activities. Cyclovalone inhibits cell proliferation in normal and malignant prostatic cells. Cyclovalone ist orally active.
  • HY-N1181R
    Tamarixetin (Standard)
    		Inhibitor
    Tamarixetin (Standard) is the analytical standard of Tamarixetin. This product is intended for research and analytical applications. Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC50 of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and AKT pathways.